Efficacy and safety of sugammadex in the reversal of deep neuromuscular blockade induced by rocuronium in patients with end-stage renal disease: A comparative prospective clinical trial

CONCLUSION: In patients with renal failure, sugammadex (4 mg kg−1) effectively and safely reversed profound rocuronium induced neuromuscular block, but the recovery was slower than healthy patients. TRIAL REGISTRATION: Clinicaltrials.gov identifier NCT01785758.
Source: European Journal of Anaesthesiology - Category: Anesthesiology Tags: Neuromuscular blocking agents Source Type: research